Citadel Advisors’s Mangoceuticals MGRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$80.9K Sell
189,004
-149,960
-44% -$66.5K ﹤0.01% 13075
2026
Q2
$129K Buy
+338,964
New +$131K ﹤0.01% 12477
2024
Q3
– Sell
-8,880
Closed -$41.2K – 14843
2024
Q2
$41.2K Buy
8,880
+1,253
+16% +$5.8K ﹤0.01% 11963
2024
Q1
$25.2K Buy
7,627
+6,140
+413% +$24.4K ﹤0.01% 12844
2023
Q4
$6.18K Sell
1,487
-1,658
-53% -$14.7K ﹤0.01% 13369
2023
Q3
$41.5K Buy
+3,145
New +$58.9K ﹤0.01% 11965

Other funds holding MGRX

Citadel Advisors's MGRX Position: Q3 2026 in Review

Citadel Advisors reduced its Mangoceuticals (MGRX) stake by 44% in Q3 2026, selling an estimated $66.5K and leaving 189,004 shares worth $80.9K. The position accounts for ﹤0.01% of the portfolio, ranked #13075.

Citadel Advisors first reported a position in MGRX in Q3 2023 and has held it in 6 quarters since. The position peaked at $129K in Q2 2026. 19 funds tracked by Wall St. Rank hold MGRX as of Q3 2026.

  • Citadel Advisors held 189,004 shares of Mangoceuticals worth $80.9K as of Q3 2026.
  • Citadel Advisors sold 149,960 Mangoceuticals shares in Q3 2026, an estimated $66.5K.
  • Mangoceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q3 2026, its #13075 holding.
  • Citadel Advisors first reported a position in Mangoceuticals in Q3 2023 and has held it in 6 quarters since.
  • Citadel Advisors's Mangoceuticals position peaked at $129K in Q2 2026.
  • 19 funds tracked by Wall St. Rank held Mangoceuticals as of Q3 2026.

Based on Citadel Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.